Vivek Ranka - Enfusion Head Technology
| ENFNDelisted Stock | USD 10.76 0.00 0.00% |
Executive
Vivek Ranka is Head Technology of Enfusion
| Phone | 312 253 9800 |
| Web | https://www.enfusion.com |
Enfusion Management Efficiency
The company has return on total asset (ROA) of 0.0305 % which means that it generated a profit of $0.0305 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0442 %, meaning that it created $0.0442 on every $100 dollars invested by stockholders. Enfusion's management efficiency ratios could be used to measure how well Enfusion manages its routine affairs as well as how well it operates its assets and liabilities.Enfusion currently holds 20.31 M in liabilities. Enfusion has a current ratio of 8.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Enfusion's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Mario Carvajal | Avepoint | N/A | |
| Marcus Jewell | Cellebrite DI | 53 | |
| JD Esq | Cellebrite DI | 60 | |
| Anne JD | Penguin Solutions | 49 | |
| Suzanne Schmidt | Penguin Solutions | N/A | |
| Tony Frey | Penguin Solutions | N/A | |
| Dux Sy | Avepoint | N/A | |
| Alan Marten | Penguin Solutions | 64 | |
| Wei Chen | Avepoint | N/A | |
| Richard Hazell | Penguin Solutions | 62 | |
| Andrew Kramer | Cellebrite DI | N/A | |
| Mark Seamans | Penguin Solutions | 59 | |
| David Gee | Cellebrite DI | 59 | |
| JD Cipp | Avepoint | N/A | |
| Philip Pokorny | Penguin Solutions | N/A | |
| David Barter | Cellebrite DI | 54 | |
| Taylor Davenport | Avepoint | N/A | |
| Michael Wellman | Penguin Solutions | N/A | |
| Brian JD | Avepoint | 54 | |
| Arnon Zilberman | Cellebrite DI | N/A | |
| Zohar TadmorEilat | Cellebrite DI | 53 | |
Management Performance
| Return On Equity | 0.0442 | |||
| Return On Asset | 0.0305 |
Enfusion Leadership Team
Elected by the shareholders, the Enfusion's board of directors comprises two types of representatives: Enfusion inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enfusion. The board's role is to monitor Enfusion's management team and ensure that shareholders' interests are well served. Enfusion's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enfusion's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Stephen Dorton, Chief Officer | ||
| Michael Berry, Chief Officer | ||
| Lorelei Skillman, Chief Officer | ||
| Vivek Ranka, Head Technology | ||
| Stephen Malherbe, Managing Partner | ||
| Oleg Movchan, Interim Director | ||
| Matthew Campobasso, General Secretary | ||
| Bronwen Bastone, Chief Officer | ||
| Joseph Defeo, Global Production | ||
| Lotte Tonsberg, Head EMEA | ||
| Kabir Kohli, MD Services | ||
| Jeff Young, Head Implementation | ||
| Iris Wang, Chief Officer | ||
| Brian Murphy, Investor | ||
| Matt Campobasso, General Counsel | ||
| Robert Taylor, Head Support | ||
| Ignatius Njoku, Head Relations | ||
| Bradley Herring, Chief Officer | ||
| Neal Pawar, Chief Officer | ||
| Daniel Groman, Chief Officer | ||
| Valeria Gutowski, Chief Officer |
Enfusion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enfusion a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0442 | |||
| Return On Asset | 0.0305 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.03 % | |||
| Current Valuation | 1.01 B | |||
| Shares Outstanding | 94.8 M | |||
| Shares Owned By Insiders | 4.73 % | |||
| Shares Owned By Institutions | 96.25 % | |||
| Number Of Shares Shorted | 1.3 M | |||
| Price To Earning | 0.11 X |
Pair Trading with Enfusion
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Enfusion position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enfusion will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Enfusion could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Enfusion when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Enfusion - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Enfusion to buy it.
The correlation of Enfusion is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Enfusion moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Enfusion moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Enfusion can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Other Consideration for investing in Enfusion Stock
If you are still planning to invest in Enfusion check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Enfusion's history and understand the potential risks before investing.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |